|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Utilizing the Decipher® mRNA Score for Risk Stratification in mHSPC
|
| David Morris, MD, FACS |
| Ashley Ross and David Morris discuss the use of the Decipher® Genomic Classifier in metastatic hormone-sensitive prostate cancer (mHSPC). They explore how Decipher® can help stratify patients and guide treatment decisions, particularly in choosing between monotherapy, doublet, or triplet therapies. |
|
|
|
|
|
|
|
|
|
|
|
|
ProBio Trial Demonstrates Improved Outcomes Using Biomarker-Guided Therapy Selection for Metastatic Prostate Cancer
|
|
Henrik Grönberg, MD, PhD
|
| Zachary Klaassen interviews Henrik Grönberg about the ProBio trial, presented at ESMO 2023. The ProBio trial, designed in 2019, is a platform trial aimed at determining the optimal treatment sequence for metastatic prostate cancer and identifying predictive biomarkers for treatment efficacy.
|
|
|
|
|
|
|
|
|
|
|
|
| Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication |
Susan Halabi, PhD
Susan Halabi discusses her presentation on prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) based on the Alliance trial. The phase three trial, which enrolled 1,311 patients, compared the effects of enzalutamide alone to enzalutamide combined with abiraterone and prednisone. |
|
|
|
|
|
|
|
|
|
|
| Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data Set - Beyond the Abstract |
| Helen Sun, MD, & Randy Vince Jr., MD, MS |
| This study evaluated the clinical utility of polygenic risk scores (PRS) for predicting prostate cancer incidence and aggressiveness in a large biobank dataset. While higher PRS correlated with increased prostate cancer incidence, they showed no association with disease aggressiveness across biopsy- or pathology-based risk categories. Future work aims to enhance PRS by integrating diverse populations and clinical variables like PSA and family history to improve detection of clinically significant prostate cancer.4o |
|
|
|
|
|
| Decipher® mRNA Score for Prediction of Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy for Advanced Prostate Cancer: An Ancillary Study of the STAMPEDE Docetaxel Trials |
| Emily Grist, MBBS, PhD |
| An ancillary study of the STAMPEDE Docetaxel trial assessed the Decipher® mRNA score as a predictive biomarker for survival benefit with docetaxel intensification in metastatic hormone-sensitive prostate cancer (mHSPC). A high Decipher® score identified patients more likely to benefit from docetaxel addition to ADT, particularly in low-volume disease (HR 0.53). |
|
|
|
|
|
| A Clinical-Genetic ctDNA-Based Prognostic Model for Predicting OS in Men with mCRPC Treated with Potent Androgen Receptor Inhibition (Alliance) |
| Susan Halabi, PhD |
| Susan Halabi presented a clinical-genetic ctDNA-based prognostic model to predict overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition. The model, developed using data from the A031201 phase 3 trial, includes both clinical factors and 16 ctDNA genetic alterations, with key predictors like AR and MYC gains, PTEN and ZBTB16 losses, and hemoglobin levels. |
|
|
|
|
|
|
|
|
|
|
| Prognosis is in the Blood |
| Gerhardt Attard, MD, PhD |
| Gerhardt Attard discusses two key abstracts on circulating tumor DNA (ctDNA) in prostate cancer, emphasizing its clinical potential in prognostication, treatment prediction, and response assessment. He highlighted Dr. Susan Halabi's work on a ctDNA-based model for predicting survival in metastatic castrate-resistant prostate cancer (mCRPC), which identified key genetic factors, and Dr. Johann De Bono's study on baseline ctDNA dynamics in patients treated with LuPSMA. |
|
|
|
|
|
| Practical Approach to Genetic Testing and Treatment Selection in Prostate Cancer. |
| David James VanderWeele, MD, PhD |
| David VanderWeele outlines a practical approach to genetic testing and treatment selection for prostate cancer, emphasizing the role of somatic and germline testing in guiding therapy. He discusses the importance of testing for mutations like BRCA2, which can influence treatment options such as PARP inhibitors, and highlighted the potential for personalized treatment plans based on genetic alterations. |
|
|
|
|
|
|
|
|
|
|
